AI
~MIVT $1.28 $1.29 News...GM All!...
MIV Therapeutics Spotlights Newest Clinical Results of Company's HAp-Based Stent Coating on BiomedDiscoveries.com; Chief Medical Officer Describes Positive Outcomes of Pivotal Study of Biocompatibility Coatings in Interview
Dec 15, 2005 3:30:00 AM
Copyright Business Wire 2005
LOS ANGELES--(BUSINESS WIRE)--Dec. 15, 2005--
BiomedDiscoveries.com -- http://www.BiomedDiscoveries.com, the online source for exclusive investor information in the biotechnology sector, today announced the online availability of a new Q&A style interview with Dr. Dov Shimon, Chief Medical Officer and Director of MIV Therapeutics (OTCBB:MIVT) (FWB:MIV), a leading developer of new generation biocompatible coatings and advanced drug delivery systems.
In the interview, Dr. Shimon provides details of results from a pivotal long-term animal study of MIVT's proprietary Ultra-thin Hydroxyapatite (HAp) coating. In the recently completed study, a coronary stent coated with MIVT's HAp formulation was implanted in a porcine coronary artery. The coating was then studied over a six-month period to examine its biocompatibility, safety and efficacy in the animal's body.
The results showed the HAp coating to have, "superb compatibility and zero reactivity," Dr. Shimon said. "A number of variables were looked at in the study -- the exact measure of narrowing inside the stent reaction, beyond the stent, etc. -- and we're happy to report that there have been no adverse effects or reactions to the coating material."
He continued, "There are over one million patients every year who undergo implantation of coronary stents in the United States alone, to give an idea of how many patients' lives could be affected and improved by MIV Therapeutics' leadership in optimizing stent coating safety."
The study was performed at the Center for Research in Cardiovascular Interventions of the Methodist Hospital Research Institute, an independent research organization that is highly distinguished in the field.
Stents are coil-like metal devices that are used to prop open blocked arteries in cardiac patients. The results are expected to help pave the way to upcoming clinical trials with humans volunteers, and ultimately, to the Company's planned commercialization of this possible breakthrough technology in the fast-growing, multi-billion-dollar global stent marketplace.
MIVT has developed a portfolio of patented HAp coating technologies based on an organic substance found in human bone and teeth, in order to eliminate serious risks that are often associated with today's generation of polymer-based coatings on the market. The Q&A interview can be read free of charge by visiting http://www.BiomedDiscoveries.com.
About MIV Therapeutics, Inc.
MIV Therapeutics, Inc. is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting application on cardiovascular stents and for application on a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed primarily to protect surrounding tissue from the chemical interaction with metal stents. The Company's unique ultra-thin coating has been derived from a biocompatible material called Hydroxyapatite (HAp) that during in-vivo animal trials demonstrated excellent safety and exceptional biocompatibility pursued by the science in the field of advanced implantable drug delivery systems. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth. It is widely used as a bone substitute material and for coating implantable fixation devices in orthopedic, dental and other applications. The Company's novel drug-eluting technologies based on Hydroxyapatite provide an attractive alternative solution to polymer-based drug-eluting coatings currently in the stent market. The Company's drug-eluting coating is designed to suit a broad range of implantable medical devices which may benefit from a highly customizable drug release profile. MIVT reached a Collaborative Research Agreement (CRA) with the University of British Columbia and supported a research and development grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) in 2002 for the development of Hydroxyapatite as a drug-eluting coating. In December 2004 MIVT received a Government grant for the research program titled "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents" under the National Research Council -- Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship the Company will progress to the development stage, which is expected to finalize the drug-eluting research and development Program. For more information, please visit http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. MIVT is traded on the Frankfurt, Germany, stock exchange under the symbol MIV.
About BiomedDiscoveries.com
BiomedDiscoveries.com provides exclusive commentary, research, interviews and other information about the smallcap investment marketplace. BiomedDiscoveries.com strives to provide investors with information and research-based data regarding important individual companies and overall marketplace trends. Resources available on BiomedDiscoveries.com include audio interviews with corporate leaders and respected commentators, as well as technical white papers and other forms of market and investment analysis. It is located at http://www.BiomedDiscoveries.com.
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Compensation and Other Disclosures
BiomedDiscoveries.com is a wholly owned subsidiary of Trilogy Capital Partners, Inc. Trilogy Capital Partners provides investor relations services to public companies. The companies presented by BiomedDiscoveries.com are usually clients of Trilogy Capital Partners and compensate Trilogy Capital Partners for these services, including cash compensation and equity securities. In addition, Trilogy Capital Partners and its affiliates may own securities of the presenting companies, and may from time to time purchase and sell securities of these companies in the open market or in private transactions. Trilogy receives compensation from MIV Therapeutics of $10,000 per month through November 2005 and thereafter for so long as Trilogy is retained to provide investor relations services. Trilogy has non-transferable warrants from this company to purchase 2,720,000 shares of common stock for $0.26 per share and expiring in November 2007, provided that Trilogy may not exercise the warrants to the extent that following such exercise Trilogy would beneficially own 5% or more or the outstanding common stock of this company.
Source: BiomedDiscoveries.com
----------------------------------------------
BiomedDiscoveries.com
Astra Thomas
800-592-6061
MIV Therapeutics Spotlights Newest Clinical Results of Company's HAp-Based Stent Coating on BiomedDiscoveries.com; Chief Medical Officer Describes Positive Outcomes of Pivotal Study of Biocompatibility Coatings in Interview
Dec 15, 2005 3:30:00 AM
Copyright Business Wire 2005
LOS ANGELES--(BUSINESS WIRE)--Dec. 15, 2005--
BiomedDiscoveries.com -- http://www.BiomedDiscoveries.com, the online source for exclusive investor information in the biotechnology sector, today announced the online availability of a new Q&A style interview with Dr. Dov Shimon, Chief Medical Officer and Director of MIV Therapeutics (OTCBB:MIVT) (FWB:MIV), a leading developer of new generation biocompatible coatings and advanced drug delivery systems.
In the interview, Dr. Shimon provides details of results from a pivotal long-term animal study of MIVT's proprietary Ultra-thin Hydroxyapatite (HAp) coating. In the recently completed study, a coronary stent coated with MIVT's HAp formulation was implanted in a porcine coronary artery. The coating was then studied over a six-month period to examine its biocompatibility, safety and efficacy in the animal's body.
The results showed the HAp coating to have, "superb compatibility and zero reactivity," Dr. Shimon said. "A number of variables were looked at in the study -- the exact measure of narrowing inside the stent reaction, beyond the stent, etc. -- and we're happy to report that there have been no adverse effects or reactions to the coating material."
He continued, "There are over one million patients every year who undergo implantation of coronary stents in the United States alone, to give an idea of how many patients' lives could be affected and improved by MIV Therapeutics' leadership in optimizing stent coating safety."
The study was performed at the Center for Research in Cardiovascular Interventions of the Methodist Hospital Research Institute, an independent research organization that is highly distinguished in the field.
Stents are coil-like metal devices that are used to prop open blocked arteries in cardiac patients. The results are expected to help pave the way to upcoming clinical trials with humans volunteers, and ultimately, to the Company's planned commercialization of this possible breakthrough technology in the fast-growing, multi-billion-dollar global stent marketplace.
MIVT has developed a portfolio of patented HAp coating technologies based on an organic substance found in human bone and teeth, in order to eliminate serious risks that are often associated with today's generation of polymer-based coatings on the market. The Q&A interview can be read free of charge by visiting http://www.BiomedDiscoveries.com.
About MIV Therapeutics, Inc.
MIV Therapeutics, Inc. is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting application on cardiovascular stents and for application on a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed primarily to protect surrounding tissue from the chemical interaction with metal stents. The Company's unique ultra-thin coating has been derived from a biocompatible material called Hydroxyapatite (HAp) that during in-vivo animal trials demonstrated excellent safety and exceptional biocompatibility pursued by the science in the field of advanced implantable drug delivery systems. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth. It is widely used as a bone substitute material and for coating implantable fixation devices in orthopedic, dental and other applications. The Company's novel drug-eluting technologies based on Hydroxyapatite provide an attractive alternative solution to polymer-based drug-eluting coatings currently in the stent market. The Company's drug-eluting coating is designed to suit a broad range of implantable medical devices which may benefit from a highly customizable drug release profile. MIVT reached a Collaborative Research Agreement (CRA) with the University of British Columbia and supported a research and development grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) in 2002 for the development of Hydroxyapatite as a drug-eluting coating. In December 2004 MIVT received a Government grant for the research program titled "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents" under the National Research Council -- Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship the Company will progress to the development stage, which is expected to finalize the drug-eluting research and development Program. For more information, please visit http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. MIVT is traded on the Frankfurt, Germany, stock exchange under the symbol MIV.
About BiomedDiscoveries.com
BiomedDiscoveries.com provides exclusive commentary, research, interviews and other information about the smallcap investment marketplace. BiomedDiscoveries.com strives to provide investors with information and research-based data regarding important individual companies and overall marketplace trends. Resources available on BiomedDiscoveries.com include audio interviews with corporate leaders and respected commentators, as well as technical white papers and other forms of market and investment analysis. It is located at http://www.BiomedDiscoveries.com.
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Compensation and Other Disclosures
BiomedDiscoveries.com is a wholly owned subsidiary of Trilogy Capital Partners, Inc. Trilogy Capital Partners provides investor relations services to public companies. The companies presented by BiomedDiscoveries.com are usually clients of Trilogy Capital Partners and compensate Trilogy Capital Partners for these services, including cash compensation and equity securities. In addition, Trilogy Capital Partners and its affiliates may own securities of the presenting companies, and may from time to time purchase and sell securities of these companies in the open market or in private transactions. Trilogy receives compensation from MIV Therapeutics of $10,000 per month through November 2005 and thereafter for so long as Trilogy is retained to provide investor relations services. Trilogy has non-transferable warrants from this company to purchase 2,720,000 shares of common stock for $0.26 per share and expiring in November 2007, provided that Trilogy may not exercise the warrants to the extent that following such exercise Trilogy would beneficially own 5% or more or the outstanding common stock of this company.
Source: BiomedDiscoveries.com
----------------------------------------------
BiomedDiscoveries.com
Astra Thomas
800-592-6061
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
